Table 5.
IP1 Mean ± SD |
IP2 Mean ± SD |
IP3 Mean ± SD |
IP4 Mean ± SD |
PP Mean ± SD |
p | |
---|---|---|---|---|---|---|
N (F/M) | 17 (14/3) | 15 (14/1) | 16 (15/1) | 17 (15/2) | 15 (14/1) | |
INFLAMMATORY
MARKERS |
||||||
CRP (mg/L) | ||||||
Baseline | 1.82 ± 1.31 | 2.25 ± 1.58 | 1.02 ± 0.38 | 1.54 ± 1.60 | 1.45 ± 0.98 | 0.345 |
After 4 weeks | 1.71 ± 1.70 | 2.39 ± 1.97 | 1.16 ± 1.27 | 1.20 ± 1.03 | 1.40 ± 0.96 | 0.671 |
After 8 weeks | 1.64 ± 1.35 a | 1.63 ± 1.50 a | 1.09 ± 0.69 | 1.22 ± 1.24 a | 1.68 ± 1.36 | 0.041 b |
IL-6 (pg/mL) | ||||||
Baseline | 2.18 ± 1.07 | 4.51 ± 2.88 | 1.59 ± 0.26 | 1.61 ± 0.75 | 2.13 ± 1.45 | 0.293 |
After 4 weeks | 2.96 ± 2.41 | 2.24 ± 1.16 | 1.49 ± 0.75 | 1.34 ± 0.66 | 1.98 ± 1.15 | 0.082 |
After 8 weeks | 2.88 ± 1.52 | 2.97 ± 1.49 | 1.88 ± 0.59 | 2.49 ± 1.77 | 3.36 ± 3.77 | 0.395 |
TNF-α (pg/mL) | ||||||
Baseline | 0.21 ± 0.06 | 0.23 ± 0.07 | 0.19 ± 0.05 | 0.21 ± 0.04 | 0.23 ± 0.07 | 0.861 |
After 4 weeks | 0.17 ± 0.02 | 0.21 ± 0.03 | 0.17 ± 0.04 | 0.18 ± 0.04 | 0.22 ± 0.05 | 0.965 |
After 8 weeks | 0.23 ± 0.07 | 0.19 ± 0.06 | 0.19 ± 0.04 | 0.20 ± 0.07 | 0.26 ± 0.09 | 0.689 |
GUT PERMEABILITY | ||||||
LBP (µg/mL) | ||||||
Baseline | 10.6 ± 1.6 | 11.2 ± 4.1 | 10.2 ± 5.8 | 10.8 ± 1.3 | 11.4 ± 4.2 | 0.990 |
After 4 weeks | 12.2 ± 2.0 a | 9.5 ± 4.9 a | 6.5 ± 6.0 | 7.5 ± 2.2 a | 9.7 ± 5.1 | 0.419 |
After 8 weeks | 10.1 ± 2.0 | 12.9 ± 3.9 | 7.9 ± 4.1 | 11.9 ± 5.6 | 10.3 ± 5.0 | 0.501 |
ANOVA was performed to compare means at baseline or change at week 4 or 8 weeks from baseline between groups. p a-value denotes significant (p < 0.05) difference from the initial value within group determined by Student’s paired-samples t-test or Wilcoxon signed-rank test; p b-value denotes differences in change at week 4 or 8 weeks from baseline between groups determined by one-way ANOVA.